ABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval

Stock News

Aug 20

ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS G12C inhibitor citrate golaresetib tablets for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations has been approved by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration.

In March 2025, the company's subsidiary reached a collaboration agreement with Shanghai Allist Pharmaceuticals regarding the combination use of ABSK043 and citrate golaresetib tablets. The approved study is "An open-label Phase II clinical trial evaluating the safety, tolerability, and efficacy of ABSK043 combined with citrate golaresetib tablets in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1128157469"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128157469\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128157469?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-20 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128157469","market":"fut","top_or_hot":-1,"title":"ABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval","media":"Stock News","content":"<p>ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS G12C inhibitor citrate golaresetib tablets for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations has been approved by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration.</p>\n<p>In March 2025, the company's subsidiary reached a collaboration agreement with Shanghai Allist Pharmaceuticals regarding the combination use of ABSK043 and citrate golaresetib tablets. The approved study is \"An open-label Phase II clinical trial evaluating the safety, tolerability, and efficacy of ABSK043 combined with citrate golaresetib tablets in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-20 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS G12C inhibitor citrate golaresetib tablets for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations has been approved by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration.</p>\n<p>In March 2025, the company's subsidiary reached a collaboration agreement with Shanghai Allist Pharmaceuticals regarding the combination use of ABSK043 and citrate golaresetib tablets. The approved study is \"An open-label Phase II clinical trial evaluating the safety, tolerability, and efficacy of ABSK043 combined with citrate golaresetib tablets in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169590202.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"","article_id":"1128157469","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128157469","pubTimestamp":1755689504,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","688578":"艾力斯","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","PD":"PagerDuty, Inc.","BK4017":"黄金","02256":"和誉-B","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK0239":"医药制造","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","09939":"开拓药业-B","LU1223082196.USD":"施罗德环球黄金A Acc","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","BK1161":"生物科技","CDE":"科尔黛伦矿业","BK1515":"抗疫概念","BK4023":"应用软件","BK1574":"生物医药B类股"},"translate_title":"和必施-B（02256）：口服PD-L1抑制剂ABSK043与上海艾利斯特KRAS G12C抑制剂联合疗法治疗非小细胞肺癌IND申请获CDE批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"688578":1,"02256":1,"09939":1,"CDE":1,"PD":1},"content_text":"ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS G12C inhibitor citrate golaresetib tablets for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations has been approved by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration.\nIn March 2025, the company's subsidiary reached a collaboration agreement with Shanghai Allist Pharmaceuticals regarding the combination use of ABSK043 and citrate golaresetib tablets. The approved study is \"An open-label Phase II clinical trial evaluating the safety, tolerability, and efficacy of ABSK043 combined with citrate golaresetib tablets in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}